Cited 42 times in
Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 이용호 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2020-12-01T17:34:56Z | - |
dc.date.available | 2020-12-01T17:34:56Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180336 | - |
dc.description.abstract | Despite the benefits of pioglitazone in the treatment of non-alcoholic fatty liver disease (NAFLD), many treated patients continue to experience disease progression. We aimed to investigate the additive effect of ipragliflozin on NAFLD in patients with type 2 diabetes treated with metformin and pioglitazone. In this 24-week randomized controlled trial, 44 patients with type 2 diabetes and comorbid NAFLD were either randomized to receive 50 mg/day of ipragliflozin as an add-on treatment (n = 29) or maintained on metformin and pioglitazone (n = 15). The fatty burden was assessed using the fatty liver index, NAFLD liver fat score, and controlled attenuation parameter (CAP). Changes in fat and muscle depots were measured by dual-energy x-ray absorptiometry and abdominal computed tomography scans. The enrolled patients were relatively controlled (mean baseline glycated hemoglobin of 6.6% ± 0.6%) and centrally obese (mean waist circumference of 101.6 ± 10.9 cm). At week 24, patients in the ipragliflozin add-on group exhibited reduced hepatic fat content (fatty liver index: -9.8 ± 1.9, p = 0.002; NAFLD liver fat score: -0.5 ± 0.2, p = 0.049; CAP: -8.2 ± 7.8 dB/m2, p = 0.133). Ipragliflozin add-on therapy also reduced whole-body visceral fat and the ratio of visceral to subcutaneous fat (change in whole-body visceral fat: -69.6 ± 21.5 g; change in abdominal visceral fat: -26.2 ± 3.7 cm2; abdominal visceral to subcutaneous fat ratio: -0.15 ± 0.04; all p < 0.05). In conclusion, ipragliflozin treatment significantly ameliorates liver steatosis and reduces excessive fat in euglycemic patients with type 2 diabetes and NAFLD taking metformin and pioglitazone. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI AG | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Eugene Han | - |
dc.contributor.googleauthor | Yong-Ho Lee | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.contributor.googleauthor | Bong-Soo Cha | - |
dc.identifier.doi | 10.3390/jcm9010259 | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A02989 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J03556 | - |
dc.identifier.eissn | 2077-0383 | - |
dc.identifier.pmid | 31963648 | - |
dc.subject.keyword | non-alcoholic fatty liver disease | - |
dc.subject.keyword | obesity | - |
dc.subject.keyword | sodium/glucose cotransporter 2 inhibitor | - |
dc.subject.keyword | type 2 diabetes mellitus | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | 강은석 | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.contributor.affiliatedAuthor | 이용호 | - |
dc.contributor.affiliatedAuthor | 차봉수 | - |
dc.citation.volume | 9 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 259 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, Vol.9(1) : 259, 2020-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.